Interestingly, several teams report different clinical cases involving breast (55, 56), ovarian (35, 57), pancreatic (58), and prostate cancers (59), highlighting that PARPi resistance mechanisms would be shared between cancers of the BRCA1/2 spectrum. This evidence concerns the gene BRCA1 and prostate carcinoma.